Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00678652 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Safety and Immunogenicity of Meningococcal Vaccine
A Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00678652 is a Phase 1 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 36 participants.
The verdict
NCT00678652, a Phase 1 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a vaccine based on outer membrane vesicles (NOMV) from genetically detoxified group B meningococcus is safe and effective for use as a vaccine. If so, the NOMV in this vaccine will be combined with NOMV from two other genetically modified strains as a potentially globally effective vaccine against group B meningococcus.
Interventions
- BIOLOGICAL 10 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine
- BIOLOGICAL 25 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine
- BIOLOGICAL 50 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine
- BIOLOGICAL 75 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00678652
The ClinicalTrials.gov registry entry for NCT00678652 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which 10 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine is the first listed.
NCT00678652 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00678652 about?
NCT00678652 is a clinical study titled "Phase 1 Safety and Immunogenicity of Meningococcal Vaccine". The purpose of this study is to determine whether a vaccine based on outer membrane vesicles (NOMV) from genetically detoxified group B meningococcus is safe and effective for use as a vaccine. If so, the NOMV in this vaccine will be combined with NOMV from two other genetically modified strains as ...
What is the current status of trial NCT00678652?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2008-04. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00678652?
The interventions under investigation include: 10 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine (BIOLOGICAL), 25 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine (BIOLOGICAL), 50 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine (BIOLOGICAL), 75 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00678652?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.